Ronan Talty
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ronan Talty has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Alice Wang
Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA
1 shared publication - Christine J. Ko
Department of Dermatology Yale School of Medicine New Haven Connecticut USA
1 shared publication Goran Micevic
Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA
1 shared publication- Kelly Olino
Department of Surgery, Yale School of Medicine, New Haven, CT 06511, USA
1 shared publication - William Damsky
Department of Dermatology, Yale School of Medicine , New Haven, CT
1 shared publication
Latest Publications
- Open Access
- 5 August 2022
- Published by S. Karger AG in Case Reports in Dermatology
- Vol. 14 (2) , 214-218
Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist
Leukoderma, or hypomelanosis of the skin, can occur in response to various chemical and pharmacologic substances ranging from topical medications to optic preparations and systemic medications. In this case report, we present a 78-year-old man with a history of restless leg syndrome (RLS) who had been using rotigotine transdermal patches once daily for 1 year and developed leukoderma on the bilateral anterior shoulders in the area of patch application. Histopathologic examination showed an absence of melanocytes at the dermal-epidermal junction confirmed by Melan A stain. While the patient was not bothered by the depigmentation and elected to continue the rotigotine patch for his RLS, this case highlights leukoderma as a potential side effect of dopamine transdermal patches and offers insight into the potential mechanism of hypopigmentation in response to dopamine agonism.
- 5 August 2022
- Published by S. Karger AG in Case Reports in Dermatology
- Vol. 14 (2) , 214-218
Open AccessLeukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist
Leukoderma, or hypomelanosis of the skin, can occur in response to various chemical and pharmacologic substances ranging from topical medications to optic preparations and systemic medications. In this case report, we present a 78-year-old man with a history of restless leg syndrome (RLS) who had been using rotigotine transdermal patches once daily for 1 year and developed leukoderma on the bilateral anterior shoulders in the area of patch application. Histopathologic examination showed an absence of melanocytes at the dermal-epidermal junction confirmed by Melan A stain. While the patient was not bothered by the depigmentation and elected to continue the rotigotine patch for his RLS, this case highlights leukoderma as a potential side effect of dopamine transdermal patches and offers insight into the potential mechanism of hypopigmentation in response to dopamine agonism.
- Open Access
Metabolism of Innate Immune Cells in Cancer
Cancer cells possess specific metabolic requirements for their survival, proliferation, and progression. Within a shared microenvironment, immune cells depend on competing metabolic pathways for their development and effector function. As a result, local acidification, hypoxia, and nutrient depletion in the tumor microenvironment can alter the antitumor immune response and even promote resistance to immunotherapies such as immune checkpoint blockade and adoptive cell transfer. Although T cells are the primary effectors of the antitumor response, growing evidence demonstrates that innate immune cells are critical to successful tumor clearance. This review aims to summarize current research related to the innate immune system, metabolism, and cancer. We first discuss the specific metabolic requirements of innate immune cells for immune activation and suppression and conclude by highlighting ongoing clinical applications of these findings.
Open AccessMetabolism of Innate Immune Cells in Cancer
Cancer cells possess specific metabolic requirements for their survival, proliferation, and progression. Within a shared microenvironment, immune cells depend on competing metabolic pathways for their development and effector function. As a result, local acidification, hypoxia, and nutrient depletion in the tumor microenvironment can alter the antitumor immune response and even promote resistance to immunotherapies such as immune checkpoint blockade and adoptive cell transfer. Although T cells are the primary effectors of the antitumor response, growing evidence demonstrates that innate immune cells are critical to successful tumor clearance. This review aims to summarize current research related to the innate immune system, metabolism, and cancer. We first discuss the specific metabolic requirements of innate immune cells for immune activation and suppression and conclude by highlighting ongoing clinical applications of these findings.